

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 17/00, A61K 31/70	A1	(11) International Publication Number: WO 91/19726 (43) International Publication Date: 26 December 1991 (26.12.91)
<p>(21) International Application Number: PCT/US91/04289</p> <p>(22) International Filing Date: 14 June 1991 (14.06.91)</p> <p>(30) Priority data: 539,001 15 June 1990 (15.06.90) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 539,001 (CIP) Filed on 15 June 1990 (15.06.90)</p> <p>(71) Applicants (for all designated States except US): WAKE FOREST UNIVERSITY [US/US]; Office of Research Development, 300 South Hawthorne Road, Winston-Salem, NC 27103 (US).</p> <p>(71) Applicant (for all designated States except US): THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; Office of Research Services, 300 Bynum Hall - Campus Box 4100, Chapel Hill, NC 27599-4100 (US).</p>		<p>(72) Inventors; and (75) Inventors/Applicants (for US only): PIANTADOSI, Claude [US/US]; 701 Kings Mill Road, Chapel Hill, NC 27514 (US). MARASCO, Canio, J., Jr. [US/US]; 2525 Booker Creek Road, Apartment 9-A, Chapel Hill, NC 27514 (US). KUCERA, Louis, S. [US/US]; 4860 Ellen Avenue, Pfafftown, NC 27040 (US).</p> <p>(74) Agents: SIBLEY, Kenneth, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).</p> <p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published With international search report.</p>
<p>(54) Title: ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES</p> <p>(57) Abstract</p> <p>Ether lipid nucleoside covalent conjugates and derivatives thereof are disclosed, along with pharmaceutical compositions containing the same and methods of using the same to combat HIV-1 infections. Illustrative are 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3 octadecanamido-2-ethoxypropane and 3'-Azido-3'-deoxythymidine-5' butyrate-γ-N,N,N-trimethyl-ammonium-β-(1-phospho-2-ethoxy-3-hexadecyloxypropane).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES

Field of the Invention

The present invention relates to antiviral compounds in general, and particularly relates to covalent conjugates of ether lipids and antiviral nucleoside analogs, which conjugates have antiviral activity.

Background of the Invention

The currently preferred treatment for combating human immunodeficiency virus type 1 (HIV-1) infections is by the administration of 3'-azido-3'-deoxythymidine, or AZT, to an afflicted subject. See, e.g., U.S. Patent No. 4,724,232 to Rideout et al.

C. Piantadosi et al., PCT Appln No. US89 04747 (published May 17, 1990), discloses a method of combating HIV-1 infections which comprises administering various ether lipid compounds in an amount effective to inhibit replication of the virus in infected cells. See also L. Kucera et al., Aids Research and Human Retroviruses 6, 491 (1990).

Various lipid derivatives of antiviral nucleosides, and the liposomal incorporation thereof, are disclosed in PCT Application Serial No. WO 90/00555

-2-


of K. Hostetler et al. See also K. Hostetler et al.,
J. Biol. Chem 265, 6112, 6113 Fig. 1 (1990).

U.S. Patent No. 4,291,024 to Turcotte
 concerns cytotoxic liponucleotide analogs, and U.S.
 5 Patent No. 4,921,951 to Shuto et al. discloses
 antineoplastic nucleoside-phospholipid conjugates.

In spite of prior efforts, there is an
 ongoing need for new ways to treat HIV-1 infections.
 The present invention is based on our continuing
 10 research in this area.

Summary of the Invention

Disclosed herein are ether lipid-nucleoside
 covalent conjugates (or "lipid-nucleoside conjugates")
 of Formula (I) below and the salts thereof:



wherein:

R_1 is C10-C20 saturated or unsaturated alkyl
 containing not more than three double bonds.
 Preferably, R_1 is C16-C18 linear alkyl containing not
 35 more than one double bond.

R_2 is H or C1-C20 saturated or unsaturated
 alkyl containing not more than three double bonds.
 Preferably, R_2 is H or C1-C3 alkyl.

-3-

W_1 is S, O, $\text{NHC}(=\text{O})$, or NH. Preferably W_1 is $\text{NHC}(=\text{O})$.

W_2 is S, O, $\text{NHC}(=\text{O})$, $\text{OC}(=\text{O})$, NH, or a covalent bond. Preferably, W_2 is O.


5 n is zero or one.

X_1 and X_2 are each independently oxygen or a covalent bond, subject to the proviso that when n is zero, then at least either X_1 or X_2 is O.

10 Y is H, F, or N_3 ; Z is H or F; or Y and Z together are a covalent bond (i.e., form a didehydro). Preferably, Y is H or N_3 ; Z is H; or Y and Z together are a covalent bond. More preferably, Y is H or N_3 and Z is H.

15 B is a base such as adenine, thymine, cytosine, guanine, hypoxanthine, uracil, 5-fluorocytosine, 2-fluoro-adenine, 2-chloro-adenine, 2-bromo-adenine, and 2-amino-adenine.

Also disclosed herein are lipid-nucleoside conjugates of Formula (II) below and the salts thereof:



wherein:

30 X is S, O, $\text{NHC}(=\text{O})$, $\text{OC}(=\text{O})$, or NH, preferably $\text{NHC}(=\text{O})$.

R' is linear or branched, saturated or unsaturated C10-C20 alkyl containing not more than four double bonds, linear or branched, saturated or unsaturated C10-C20 acyl containing not more than four double bonds, phenyl, or naphthyl. More preferably, R' is C14-C20 linear saturated or unsaturated alkyl containing not more than three double bonds. Most

35

preferably, R' is C16-C18 linear alkyl containing not more than one double bond.

R" is C5 to C6 cycloalkylene, or a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon chain containing 2-8 carbon atoms, which is unsubstituted or substituted one or more times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino, C1-C20 alkyl, or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy. Preferably, R" is C2-C4 linear alkyl which is unsubstituted or is substituted one or two times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy. More preferably, R" is linear C2-C4 alkyl which is unsubstituted or substituted one or two times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy.


m is zero or one.

X₁ and X₂ are each independently oxygen or a covalent bond, subject to the proviso that when m is zero, then at least either X₁ or X₂ is O.

n is 1 to 3. Preferably n is 1.

R₁₃, R₁₄, and R₁₅ are each independently either hydrogen or methyl, preferably methyl.

Nuc is:




wherein:

-5-

Y' is H, F, or N₃; Z is H or F; or Y' and Z' together are a covalent bond (i.e., form a didehydro). Preferably, Y' is H or N₃; Z' is H; or Y' and Z' together are a covalent bond. More preferably, Y' is H or N₃ and Z' is H.

B' is a base such as adenine, thymine, cytosine, guanine, hypoxanthine, uracil, 5-fluorocytosine, 2-fluoro-adenine, 2-chloro-adenine, 2-bromo-adenine, and 2-amino-adenine.

A specific example of compounds of Formula (II) above are those of Formula (III) below and the salts thereof:



wherein:

R₁₁ is C10-C20 saturated or unsaturated alkyl containing not more than three double bonds.

Preferably, R₁₁ is C16-C18 linear alkyl containing not more than one double bond.

R₁₂ is H or C1-C20 saturated or unsaturated alkyl containing not more than three double bonds.

Preferably, R₁₂ is H or C1-C3 alkyl.

W₃ is S, O, NHC(=O), OC(=O), or NH. Preferably W₃ is NHC(=O).

W₄ is S, O, NHC(=O), OC(=O), NH, or a covalent bond. Preferably, W₄ is O.

m is zero or one.

-6-

X_1 and X_2 are each independently oxygen or a covalent bond, subject to the proviso that when m is zero, then at least either X_1 or X_2 is O.

n is 1 to 3. Preferably n is 1.

5 R_{13} , R_{14} , and R_{15} are each independently either hydrogen or methyl, preferably methyl.

Nuc is as given in connection with Formula (II) above.

10 Also disclosed are pharmaceutical compositions comprising a lipid-nucleoside conjugate according to Formula I, II, or III above in a pharmaceutically acceptable carrier, wherein the lipid-nucleoside conjugate is included in the composition in an HIV-1 combating amount.

15 Also disclosed is the use of a lipid-nucleoside conjugate according to Formula I, II or III above to prepare a pharmaceutical composition or medicament for combating an HIV-1 infection in an afflicted subject.


20 Also disclosed is a method of combating HIV-1 infections in an afflicted subject comprising administering the subject an effective HIV-1 combating amount of a lipid-nucleoside conjugate according to Formula I, II or III above.

25 Detailed Description of the Invention

Phospholipid-nucleoside conjugates of the present invention (e.g., Compounds A-D) may be prepared according to Scheme 1. The starting alcohols are synthesized as previously described. See M. Marx et al., J. Med. Chem. 31, 858 (1988); S. Morris-Natschke et al., J. Med. Chem. 29, 2114 (1986).

30

SCHEME 1
Phospholipid Nucleoside Conjugates




The amidoalkyl glycerol derivative is phosphorylated with diphenylchlorophosphate in pyridine to give the corresponding phosphate ester. See C. Piantadosi, J. Pharm. Sci. 62, 320 (1973). The phenyl groups are then removed via hydrogenolysis with PtO₂ to give the

intermediate. The thio and oxygen ether derivatives are phosphorylated by an alternative procedure using phosphorus oxychloride and triethylamine or pyridine. See Ether Lipids: Biochemical and Biomedical Aspects, 403 (H. Mayold and F. Paltauf eds. 1983); C. Hong et al., J. Med. Chem. 29, 2038 (1986). The phosphatidic acid derivatives are then conjugated to the 5' hydroxyl of the appropriate nucleoside (NUC) via a dicyclohexylcarbodiimide (DCC) condensation, and subsequent conversion to the sodium salt gave the desired products. See E. Ryu et al., J. Med. Chem. 25, 1322 (1982).

The synthesis of the phosphonate analogue (e.g., Compound E) is shown in Scheme 2.

SCHEME 2

Synthesis of Phosphonate-Nucleoside Conjugates



Starting with the appropriate bromopropane, see C. Marasco et al., J. Med. Chem. 33, 985 (1990), the halide is displaced with trimethylphosphite to afford the corresponding phosphonate. B. Arbuzov, Pure Appl. Chem. 9, 307 (1964). The protective methyl groups are


then cleaved with trimethylsilylbromide, see R. Bittman et al., Chem. Phys. Lipids 34, 201 (1984), to give the expected phosphonic acid. Condensation of the phosphonic acid intermediate with a nucleoside such as AZT is done in the usual manner to give product phosphonate.

The carnitine conjugates (e.g., Compound AA) are prepared according to Scheme 3.

10

SCHEME 3

Synthesis of Carnitine-Nucleoside Conjugates



35 The condensation of the starting intermediate with the benzyl ester of carnitine as the tetraphenylborate salt is done via a 2,4,6-triisopropylbenzenesulfonylchloride (TPS) coupling to give a benzyl esterified carnitine.

See U. Hintze and G. Gercken, Lipids 10, 20 (1974).

The benzyl ester of the esterified intermediate is then cleaved by hydrogenolysis with Pd on activated carbon to yield the free carboxylic acid. Condensation of this intermediate with a nucleoside such as AZT is then performed in the usual manner to give the expected product as the sodium salt.

The pyrophosphate or phosphonophosphate conjugates are synthesized from the condensation of the appropriate dialkyl or amidoalkyl phosphatidic or phosphonic acid derivative with the appropriate 5'-monophosphomorpholidate nucleoside as the N,N'-dicyclohexylcarboxamidinium salt in pyridine. The phosphophosphonate conjugate is synthesized in an analogous manner from the appropriate dialkyl or amidoalkyl phosphatidic acid congener and the appropriate 5'-phosphonomorpholidate nucleoside as the N,N'-dicyclohexylcarboxamidinium salt.

In case the compounds disclosed above have an asymmetric carbon atom, the present invention also concerns the enantiomeric forms. The resolution of the racemates into the enantiomeric forms can be done in the last step of the process, or in the appropriate preceding step, by known procedures, for example, by converting the racemate with an optically active reagent into a diasteriomeric pair and subsequent resolution thereof.

Exemplary antiviral nucleosides which may be covalently joined to the 5' carbon on the ribose ring to form lipid-nucleoside conjugates of the present invention include 3'-deoxythymidine; 3'-fluoro-3'-deoxythymidine; 2',3'-dideoxycytidine; 2',3'-dideoxy-5-fluoro-cytidine; 2',3'-dideoxyadenosine; 3'-azido-2',3'-dideoxyadenosine; 2'-fluoro-2',3'-dideoxyadenosine; 2',3'-dideoxy-2-fluoro-adenosine; 2',3'-dideoxy-2-chloro-adenosine; 2',3'-dideoxy-2-bromo-adenosine; 2',3'-dideoxy-2-amino-adenosine;

-11-

2',3'-dideoxyguanosine; 3'-azido-2',3'-
dideoxyguanosine; 3'-azido-2',3'-dideoxyuridine; 2',3'-
didehydro-2',3'-dideoxycytidine, and 2',3'-didehydro-
2',3'-dideoxythymidine. See generally H. Mitsuya et
5 al., Proc. Natl. Acad. Sci. USA 82, 7096 (1985); H.
Mitsuya and S. Broder, Proc. Natl. Acad. Sci. USA 83,
1911 (1986); P. Herdewijn et al.; J. Med. Chem. 30,
1276 (1987); C-H. Kim et al., J. Med. Chem. 30, 862
(1987); V. Marquez et al., Biol. Chem. Pharm. 36, 2719
10 (1987); T. Haertle et al., J. Cellular Biochem. Suppl.
11D, 65 (1987); J. Balzarini et al., Biochem. Biophys.
Res. Comm. 145 277 (1987); M. Baba et al., Biochem.
Biophys. Res. Comm. 145, 1080 (1987); R. Schinazi et
al., J. Cellular Biochem. Suppl. 11D, 74 (1987); Y.
15 Hamamoto et al., Antimicrob. Agents and Chemother. 31,
907 (1987). Conjugates of 3'-Azido-3'-deoxythymidine
are preferred.

The following compounds are illustrative of
the compounds of Formula I above. These compounds may
20 be prepared by the procedures described herein, or by
variations thereof which will be apparent to those
skilled in the art in light of the instant disclosure.

- (A) 3'-azido-3'-deoxythymidine-5'-
monophosphate-D,L-3-octadecanamido-2-ethoxypropane;
25 (B) 3'-azido-3'-deoxythymidine-5'-
monophosphate-D,L-3-hexadecyloxy-2-ethoxypropane;
(C) 3'-azido-3'-deoxythymidine-5'-
monophosphate-D,L-3-hexadecylthio-2-methoxypropane;
(D) 2',3'-dideoxyinosine-5'-monophosphate-
30 D,L-3-octadecanamido-2-ethoxypropane;
(E) 3'-Azido-3'-deoxythymidine-5'-phosphono-
D,L-3-hexadecyloxy-2-methoxypropane;
(F) 3'-Azido-3'-deoxythymidine-5'-
monophosphate-D,L-3-octadecanamido-2-
35 hexadecyloxypropane;
(G) 3'-Azido-3'-deoxythymidine-5'-
monophosphate-D,L-3-octadecanamido-2-palmitoylpropane;

-12-

- (H) 3'-Azido-3-deoxythymidine-5'-
diphosphate-D,L-3-octadecanamido-2-ethoxypropane;
- (I) 3'-Azido-3'-deoxythymidine-5'-phospho-1-
phosphono-D,L-3-octadecanamido-2-ethoxypropane;
- 5 (J) 3-Azido-3'-deoxythymidine-5'phosphono-1-
phospho-D,L-3-octadecanamido-2-ethoxypropane;
- (K) 3'-deoxythymidine-5'-monophosphate-D,L-
3-octadecanamido-2-ethoxypropane;
- (L) 3'-fluoro-3'-deoxythymidine-5'-
10 monophosphate-D,L-3-hexadecyloxy-2-ethoxypropane;
- (M) 2',3'-dideoxycytidine-5'-monophosphate-
D,L-3-hexadecylthio-2-methoxypropane;
- (N) 2',3'-dideoxy-5-fluoro-cytidine-5'-
monophosphate-D,L-3-octadecanamido-2-ethoxypropane;
- 15 (O) 2',3'-dideoxyadenosine-5'-phosphono-D,L-
3-hexadecyloxy-2-methoxypropane;
- (P) 3'-Azido-2',3'-dideoxyadenosine-5'-
monophosphate-D,L-3-octadecanamido-2-
hexadecanoylpropane;
- 20 (Q) 3'-Azido-2',3'-dideoxyadenosine-5'-
monophosphate-D,L-3-octadecanamido-2-palmitoylpropane;
- (R) 2'-fluoro-2',3'-dideoxyadenosine-5'-
diphosphate-D,L-3-octadecanamido-2-ethoxypropane;
- (S) 2',3'-didehydro-2',3'-dideoxycytidine-
25 5'-phospho-1-phosphono-D,L-3-octadecanamido-2-
ethoxypropane;
- (T) 3'-Azido-2',3'-dideoxyuridine-5'-
phosphono-1-phospho-D,L-3-octadecanamido-2-
ethoxypropane;
- 30 (U) 2',3'-Dideoxy-2-fluoro-adenosine-5'-
monophosphate-D,L-3-octadecanamido-2-ethylpropane;
- (V) 2',3'-Dideoxy-2-chloro-adenosine-5'-
monophosphate-D,L-3-hexadecyloxy-2-ethylpropane;
- (W) 2',3'-Dideoxy-2-amino-adenosine-5'-
35 monophosphate-D,L-3-hexadecylthio-2-
hexadecylthiopropene;

(X) 2',3'-Dideoxy-2-bromo-adenosine-5'-
monophosphate-D,L-3-octadecanamido-2-
octadecanamidopropane;

(Y) 2',3'-Dideoxyguanosine-5'-phosphono-D,L-
5 3-hexadecylamino-2-hexadecylaminopropane;

(Z) 3'-Azido-2',3'-dideoxyguanosine-5'-
monophosphate-D,L-3-octadecanamino-2-
hexadecyloxypropane; and

(A') 3'-Azido-3'-deoxythymidine-5'-
10 diphosphate-D,L-3-hexadecyloxy-2-ethoxypropane.

The following compounds are illustrative of
the compounds of Formula II above. These compounds may
likewise be prepared by the procedures described
herein, or variations thereof which will be apparent to
15 those skilled in the art in light of the present
disclosure.

(AA) 3'-Azido-3'-deoxythymidine-5'-butyrate-
 γ -N,N,N-trimethyl-ammonium- β -(1-phospho-2-ethoxy-3-
hexadecyloxypropane); and

(BB) 3'-Azido-3'-deoxythymidine-5'-butyrate- γ -
20 N,N,N-trimethyl-ammonium- β -(1-phospho-2-ethoxy-3-
octadecanamidopropane).

The lipid-nucleoside conjugates disclosed
herein can be prepared in the form of their
25 pharmaceutically acceptable salts or their non-
pharmaceutically acceptable salts. The non-
pharmaceutically acceptable salts are useful as
intermediates for the preparation of a pharmaceutically
acceptable salt. Pharmaceutically acceptable salts are
30 salts that retain the desired biological activity of
the parent compound and do not impart undesired
toxicological effects. Examples of such salts are (a)
acid addition salts formed with inorganic acids, for
example hydrochloric acid, hydrobromic acid, sulfuric
acid, phosphoric acid, nitric acid and the like; and
35 salts formed with organic acids such as, for example,
acetic acid, oxalic acid, tartaric acid, succinic acid,

maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-
5 toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (b) salts formed from elemental anions such as chlorine, bromine, and iodine.

The lipid-nucleoside conjugates described
10 above can be combined with an inert pharmaceutical carrier to provide a pharmaceutical composition for enteral or parenteral administration. The compounds described above being the active ingredient in these compositions, they should be included in an amount
15 effective to accomplish the intended treatment. For the preparation of these compositions, use can be made of pharmaceutical carriers adapted for all conventional forms of administration, for example, tablets, capsules, dragees, syrups, solutions, suspensions and
20 the like. As injection medium, it is preferred to use water which contains the additives usual in the case of injection solutions, such as stabilizing agents, solubilizing agents and/or buffers. Additives of this kind include, for example, human serum albumin and
25 synthetic analogs thereof, tartrate and citrate buffers, ethanol, complex formers (such as ethylenediamine-tetraacetic acid and the non-toxic salts thereof) and high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation.
30 Liquid carrier materials for injection solutions must be sterile and are preferably placed into ampules. Solid carrier materials include, for example, starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acids, high molecular weight fatty
35 acids (such as stearic acid), gelatine, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats and solid high molecular weight polymers

-15-

(such as polyethylene glycols). Compositions suitable for oral administration can, if desired, contain flavoring and/or sweetening agents.

5 A method of combating human immunodeficiency virus Type 1 (HIV-1) infection in an afflicted subject comprises administering to the subject a lipid-nucleoside conjugate as described herein in an amount effective to inhibit replication of infectious virus in the subject. Likewise, a method of combating human
10 immunodeficiency virus Type 1 (HIV-1) infection of cells comprises administering to the cells a lipid-nucleoside conjugate as described herein in an amount effective to inhibit replication of the virus in the cells. Administration of the lipid-nucleoside
15 conjugate to an afflicted subject can be carried out by any suitable means, such as by intravenous administration, intraperitoneal administration, subcutaneous administration, and oral administration.

The dosage of lipid-nucleoside conjugate to
20 be administered depends upon a variety of factors, such as mode of administration, species, age, and subject condition. Usually, the dosage to be administered is from about .05 to about 100 milligrams per kilogram of body weight, more preferably between about .1 and about
25 75 milligrams per kilogram of body weight, and most preferably between about .5 and about 50 milligrams per kilogram of body weight.

In the Examples below, proton nuclear magnetic resonance spectra were recorded in CDCl_3 on
30 either a BRUKER 300-MHz or a VARIAN 400-MHz spectrometer. Chemical shifts are reported in parts per million relative to internal tetramethylsilane. Infrared spectra were recorded on a Perkin-Elmer 1320 spectrometer as thin films. Melting points were
35 determined on a Thomas-Hoover capillary melting point apparatus and are uncorrected. Microanalyses were performed by Atlantic Microlab Inc. Mass spectral data

-16-

was obtained from a VG70S Mass spectrometer. All reactions were performed under a positive pressure of dry nitrogen with dry solvents. Tetrahydrofuran (THF) was distilled from Na and benzophenone, dichloromethane (DCM) from phosphorus pentoxide, triethylamine (Et_3N) from KOH, and pyridine was stored over KOH. Chromatographic purification was performed using silica gel 60 (230-400 mesh). Thin layer chromatographic plates were visualized by iodine vapor, molybdenum phosphate spray, and charring following sulfuric acid spray.

EXAMPLE 1

(\pm)-3-Octadecanamido-2-ethoxypropyl-diphenylphosphate. To a three-neck round-bottom flask equipped with a magnetic stir bar, nitrogen inlet and reflux condenser was added a solution of (0.7 mL, 3.39 mmol) diphenylchlorophosphate in 10 mL anhydrous ether. The solution was cooled to 4°C, and a solution of the starting amidoalkyl glycerol¹ (1.0 g, 2.6 mmol) in 15 mL of pyridine and 5 mL of ether was then added. The solution was warmed to room temperature, and then heated to 52°C for 3 h. After cooling to room temperature, the reaction mixture was diluted with 50 mL of ether, extracted twice with 25 mL portions of distilled water, once with 25 mL of cold 0.5 N HCl, and once with 25 mL of distilled water. The ether layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give a pale yellow oil. Purification by silica gel chromatography (discontinuous gradient of hexane:ethyl acetate 10:1 to 1:1 as eluent) gave 961 mg of pure product (60.1%). ¹H-NMR (CDCl_3): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 31 H, $(\text{CH}_2)_{14}$, $\text{CH}_3\text{CH}_2\text{O}$], 1.55 (m, 2 H, $\text{NH-C-CH}_2\text{CH}_2$), 2.15 (t, 2 H, NH-C-CH_2), 3.3-3.6 (m, 5H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NH}$), 4.25 (m, 2 H, CH_2OP), 5.9 (t, 1 H, NH), 7.15-7.35 [m, 10 H, $(\text{OC}_6\text{H}_5)_2$].

EXAMPLE 2

(±)-3-Octadecanamide-2-ethoxypropyl-phosphatidic acid. Into a Parr hydrogenation bottle was placed a solution of 500 mg of (±)-3-Octadecanamide-2-ethoxypropyldiphenylphosphate prepared according to Example 1 above in 100 mL of absolute ethanol. To the solution was added 69 mg of PtO₂, before placement onto the hydrogenation apparatus. The reaction mixture was placed under 14.5 psi of hydrogen, and shaken at room temperature. After 100 mins, 6 psi had been consumed, and TLC (CHCl₃:MeOH:H₂O, 70:35:4) indicated the absence of starting material. The reaction mixture was suction filtered through Celite, and the ethanol removed in vacuo. The resulting oil was taken up in 25 mL of pyridine, concentrated in vacuo, and dried under vacuum to give 352 mg (93.3%) of pure product as a fine powder. ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 31 H, (CH₂)₁₄, CH₃CH₂O], 1.55 (m, 2 H, NH-C-CH₂CH₂), 2.25 (t, 2 H, NH-C-CH₂), 3.3-3.75 (m, 5 H, CH₃CH₂OCHCH₂NH), 4.15 (m, 2 H, CH₂OP), 6.7 (t, 1 H, NH).

EXAMPLE 3

(±)-3-Hexadecyloxy-2-ethoxypropyl-phosphatidic acid. To a three-neck round-bottom flask equipped with a magnetic stir bar, nitrogen inlet, and reflux condenser was added a solution of phosphorus oxychloride (0.62 mL, 6.6 mmol) in 5 mL of THF. The solution was cooled to 0°C, and a solution of the starting dialkylglycerol (2.0 g, 5.8 mmol), and pyridine (1.4 mL, 17.3 mmol) in 15 mL of THF were added. The reaction mixture was maintained at 0°C for 3 h, and then 10 mL of 10% sodium bicarbonate was added. The mixture was stirred an additional 20 min, and poured into 30 mL of ice water. The solution was acidified by the dropwise addition of 2 N HCl, and then extracted twice with 30 mL portions of ether. The

-18-

ether layer was dried over sodium sulfate, filtered, concentrated in vacuo, taken up in 100 mL of pyridine, concentrated, and dried under vacuum to give 1.5 g (46%) of product as a waxy solid. ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 29 H, (CH₂)₁₃, CH₃CH₂O], 1.4 (m, 2 H, OCH₂CH₂), 3.4-3.7 (m, 7 H, CH₃CH₂OCHCH₂OCH₂), 3.85 (m, 2 H, CH₂OP).

EXAMPLE 4

(±)-3-Hexadecylthio-2-methoxypropyl-phosphatidic acid. To a three-neck round-bottom flask equipped with a magnetic stir bar, nitrogen inlet, and reflux condenser was added a solution of phosphorus oxychloride (0.6 mL, 7 mmol) in 1 mL of hexane. The solution was cooled to 0°C, and a solution of triethylamine (1 mL, 10 mmol) in 1 mL of hexane was added dropwise. The starting thioalkyl glycerol² (1.6 g, 5 mmol) was azeotropically dried with toluene, and the volume reduced to 10 mL. This was then added dropwise to the POCl₃/Et₃N solution, and stirred overnight at room temperature. One mL of water was added to the reaction mixture and stirred for 1 h. The reaction mixture was diluted with 20 mL of water, and extracted twice with 25 mL portions of ether. The organic layers were collected, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting oil was taken up into 50 mL of pyridine, heated to 50°C for 2 h, and concentrated in vacuo. Silica gel chromatography (CHCl₃:MeOH:NH₄OH, 70:35:1 to 70:35:7 as eluent) gave 535 mg of product. ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.2 [bs, 26 H, (CH₂)₁₃], 1.4 (m, 2 H, SCH₂CH₂), 2.4 (t, 2 H SCH₂CH₂), 2.5 (m, 2H, CHCH₂S), 3.4-3.7 (m, 4 H, CH₃OCHCH₂S), 4.0 (bm, 2 H CH₂OP).

EXAMPLE 5

3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane (Compound A).

5 Into a 25 mL round-bottom flask were placed (\pm)-3-Octadenanamido-2-ethoxypropylphosphatidic acid (100 mg, 0.22 mmol) and AZT (43 mg, 0.16 mmol). The two reactants were then azeotropically dried by the *in vacuo* removal of 3 mL of pyridine three times. To this slurry dicyclohexylcarbodiimide (220 mg, 1.07 mmol) was
10 added, and once again the reactants were azeotropically dried four times with 3mL portions of pyridine. The solution was then diluted to a final volume of 3 mL, the round bottom flask stoppered, and placed in a desiccator for 4 days. One g of water was added to the
15 reaction mixture, and stirred at room temperature for 4 h. The solvents were removed *in vacuo*, and the resulting wax purified by silica gel chromatography (gradient of CHCl_3 :MeOH, 15:1 to 2:1 as eluent) to give pure product. The product was dissolved in 11 mL of
20 CHCl_3 :MeOH:H₂O (4:6:1), placed in a round bottom flask, and stirred with 1.5 g of Whatman Pre-Swollen Microgranular Cation (Na⁺) Exchange Carboxymethyl Cellulose Resin for 1 h. The resin was filtered, and the filtrate concentrated *in vacuo* to give 32 mg of
25 product as the sodium salt (21%). ¹H-NMR (CDCl_3): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 31 H, (CH_2)₁₄, $\text{CH}_3\text{CH}_2\text{O}$], 1.55 (m, 2 H, NH-C- CH_2CH_2), 1.8 (s, 3 H, Thymidine CH₃), 2.1 (t, 2 H, NH-C- CH_2), 2.2 (m, 2 H, Thymidine 2' CH₂), 3.2-3.5 (m, 5 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NH}$), 3.75
30 (m, 2 H, CH_2OP), 3.85 (m, 1 H, Thymidine 4' CH), 3.95 (m, 2 H, Thymidine 5' CH₂), 4.35 (m, 1 H, Thymidine 3' CH), 6.1 (m, 1 H, Thymidine 1' CH), 6.95 (t, 1 H, NH), 7.4 (s, 1 H, Thymidine C₆ proton), 11.3 (bs, 1 H, diimide NH). FAB Mass Spectrum (M + 2Na)⁺; Theoretical 759.3795, Observed 759.3839 (2.0 ppm).

EXAMPLE 6

3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-hexadecyloxy-2-ethoxypropane (Compound B). This analogue was made in analogous manner to that of 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropoane from 110 mg of (\pm)-3-Hexadecyloxy-2-ethoxypropylphosphatidic acid (0.26 mmol), 50 mg of AZT (0.19 mmol), and 250 mg of DCC (1.24 mmol) to give 37 mg of pure product (28%). ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 29 H, (CH₂)₁₃, CH₃CH₂O], 1.5 (m, 2 H, OCH₂CH₂), 1.8 (s, 3 H, Thymidine CH₃), 2.25 (m, 2 H, Thymidine 2' CH₂), 3.2-3.5 (m, 7 H, CH₃CH₂OCHCH₂OCH₂), 3.8 (m, 2 H, CH₂OP), 3.9 (m, 1 H, Thymidine 4' CH), 3.95 (m, 2 H, Thymidine 5' CH₂), 4.35 (m, 1 H, Thymidine 3' CH), 6.1 (m, 1 H, Thymidine 1' CH), 7.4 (s, 1 H, Thymidine C₆ proton), 11.3 (bs, 1 H, diimide NH). FAB Mass Spectrum (MH + Na)⁺; Theoretical 696.3713, Observed 696.3681 (4.6 ppm).

EXAMPLE 7

3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-hexadecylthio-2-methoxypropane (Compound C). This analogue was made in analogous manner to that of 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane (from 87 mg of (\pm)-3-hexadecylthio-2-ethoxypropyl phosphatidic acid (0.20 mmol), 43 mg of AZT (0.16 mmol), and 227 mg of DCC (1.1 mmol) to give 32 mg of pure product (23%). ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 26 H, (CH₂)₁₃], 1.45 (m, 2 H, SCH₂CH₂), 1.8 (s, 3 H, Thymidine CH₃), 2.25 (m, 2 H, Thymidine 2' CH₂), 2.4 (t, 2 H, S-CH₂), 2.6 (d, 2 H, CH₂-S), 3.3 (s, 3 H, CH₃O), 3.5 (m, 1 H, CH₃OCH), 3.9-4.1 (m, 5 H, CH₂OP, Thymidine 4' CH, 5' CH₂), 4.4 (m, 1 H, Thymidine 3' CH), 6.1 (m, 1 H, Thymidine 1' CH), 7.4 (s, 1 H, Thymidine C₆ proton), 11.3 (bs, 1 H, diimide NH). FAB Mass Spectrum (MH + Na)⁺; Theoretical 698.3328, Observed 698.3344 (2.2ppm).

-21-

EXAMPLE 8

2',3'-dideoxyinosine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane (Compound D). This analogue was made in analogous manner to that of 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane from 92 mg of (\pm)-3-Octadenanamido-2-ethoxypropyl phosphatidic acid (0.20 mmol), 35 mg of DDI (0.15 mmol), and 200 mg of DCC (1.0 mmol) to give 23 mg of pure product (22%). $^1\text{H-NMR}$ (CDCl_3); δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 31 H, (CH_2)₁₄, $\text{CH}_3\text{CH}_2\text{O}$], 1.55 (m, 2 H, $\text{NH-C-CH}_2\text{CH}_2$), 1.7 (m, 2 H Inosine 2' CH_2), 2.1 (m, 4 H, NH-C-CH_2 , Inosine 3' CH_2), 3.1-4.1 (m, 10 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NH}$, CH_2OP , Inosine 4' CH , 5' CH_2), 6.1 (m, 1 H, Inosine 1' CH), 6.95 (t, 1 H, NH), 7.4 (s, 1 H, Inosine C₈ proton), 11.3 (bs, 1 H, diimide NH). FAB Mass Spectrum ($\text{M} + 2\text{Na}$)⁺; Theoretical 728.3739, Observed 728.3738 (0.2 ppm).

EXAMPLE 9

(\pm)-3-Hexadecyloxy-2-methoxypropyl dimethylphosphonate. Into a three-neck round-bottom flask equipped with a magnetic stir bar, nitrogen inlet, and reflux condenser was placed a solution of the starting dialkyl halide, (954 mg, 2.4 mmol) in trimethylphosphite (4.987 g, 30.2 mmol). The solution was heated to 120°C for 90 h with continuous stirring. The reaction mixture was cooled to room temperature, reduced in vacuo, and purified by silica gel chromatography (gradient of petroleum ether:ether, 10:1 to 1:1 as eluent) to give 741 mg of product (80%) as a yellow viscous oil. $^1\text{H-NMR}$ (CDCl_3); δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 26 H, (CH_2)₁₃], 1.57 (m, 2 H, OCH_2CH_2), 2.08 (m, 2 H, $\text{CH}_2\text{-P}$), 3.4-3.6 (m, 7 H, $\text{CH}_3\text{OCHCH}_2\text{OCH}_2$), 3.75 [m, 7 H, CH_3OCH , $\text{P}(\text{OCH}_3)_2$].

EXAMPLE 10

(±)-3-Hexadecyloxy-2-methoxypropyl phosphonic acid. To a three-neck round-bottom flask equipped with a magnetic stir bar, nitrogen inlet, and reflux condenser was added a solution of 6 (740 mg, 1.92 mmol) in 10 mL of alcohol-free chloroform. To this solution bromotrimethylsilane (1.6 g, 10.6 mmol) was added dropwise. After 1 h the solvents were removed *in vacuo*, and the resulting oil taken up in 25 mL of THF:H₂O (8:2), and stirred overnight at room temperature. The solvents were removed *in vacuo*, and the residue recrystallized from ether:acetonitrile (1:5) to give 577 mg of pure product (85%) as a white solid (MP 59-61°C). The product was taken up into 50 mL of pyridine, the pyridine removed *in vacuo*, and then dried under vacuum. ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 26 H, (CH₂)₁₃], 1.57 (m, 2 H, OCH₂CH₂), 2.12 (m, 2 H, CH₂-P), 3.4-3.6 (m, 7 H, CH₃OCHCH₂OCH₂), 3.75 (m, 1 H, CH₃OCH).

20

EXAMPLE 11

3'-Azido-3'-deoxythymidine-5'-phosphono-D,L-3-hexadecyloxy-2-methoxypropane (Compound E). This analogue was made in analogous manner to that of 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropoane from 100 mg of (±)-3-Hexadecyloxy-2-O-methoxypropyl phosphonic acid (0.26 mmol), 50 mg of AZT (0.19 mmol), and 250 mg of DCC (1.24 mmol) to give 29 mg of pure product (23%). ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 29 H, (CH₂)₁₃, CH₃CH₂O], 1.5 (m, 2 H, OCH₂CH₂), 1.8 (s, 3 H, Thymidine CH₃), 2.25 (m, 2 H, Thymidine 2'CH₂), 3.2-3.5 (m, 7 H, CH₃CH₂OCHCH₂OCH₂), 3.7 (m, 2 H, CH₂P), 3.9 (m, 1 H, Thymidine 4' CH), 3.95 (m, 2 H, Thymidine 5' CH₂), 4.4 (m, 1 H, Thymidine 3' CH), 6.1 (m, 1 H, Thymidine 1' CH), 7.4 (s, 1 H, Thymidine C₈ proton), 11.3 (bs, 1

35

H, diimide NH). FAB Mass Spectrum (M + Na)⁺;
Theoretical 688.3426, Observed 688.3437 (1.6 ppm).

EXAMPLE 12

(±)-3-Hexadecyloxy-2-ethoxypropyl-
5 phosphosphocarnitine benzyl ester. To a three-neck
round-bottom flask equipped with a magnetic stir bar,
nitrogen inlet, and reflux condenser a solution (243
mg, 0.45 mmol) of (±)-3-hexadecyloxy-2-ethoxypropyl-
phospatidic acid in 10 mL of pyridine was added. To
10 this solution 778 mg (1.36 mmol) of the benzyl ester of
carnitine as the tetraphenylborate salt⁹, 412 mg (1.36
mmol) of 2,4,6-triisopropylbenzenesulfoyl chloride, and
an additional 15 mL of pyridine were added. The
reaction mixture was stirred continuously overnight at
15 room temperature. To the reaction mixture 2.5 mL of
distilled water was added, and stirring was continued
for 1 h. The solvents were removed *in vacuo*, and the
pale pink oil extracted three times with 30 mL portions
of ether. The extract was cooled to 0°C for 4 h,
20 filtered, and concentrated *in vacuo*. The resultant
yellow oil was purified by silica gel chromatography
(gradient CHCl₃:MeOH, 10:1 to 1:1) to give 180 mg of
pure product (56%). ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H,
terminal methyl), 1.1-1.4 [m, 29 H, (CH₂)₁₃, CH₃CH₂O],
1.5 (m, 2 H, OCH₂CH₂), 2.7 (m, 2H, P-O-CHCH₂COO-), 3.3-
25 4.3 [m, 18 H, CH₃CH₂OCHCH₂OCH₂, CH₂N(CH₃)₃], 3.85 (m, 3 H,
CH₂OPOCH), 5.1 (m, 2 H, OCH₂C₆H₅), 7.35 (bs, 5 H, C₆H₅).

EXAMPLE 13

(±)-3-Hexadecyloxy-2-ethoxypropyl-
30 phosphosphocarnitine. This analogue was made in
similar manner to that of (±)-3-Octadenanamido-2-
ethoxypropyl phospatidic acid from 110 mg of (±)-3-
Hexadecyloxy-2-ethoxypropyl phosphosphocarnitine benzyl
ester and a catalytic amount of Pd/C to give 88 mg of
35 product (93%). ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal

-24-

methyl), 1.1-1.4 [m, 29 H, (CH₂)₁₃, CH₃CH₂O], 1.5 (m, 2 H, OCH₂CH₂), 2.7 [m, 2 H, CH₂N(CH₃)₃], 3.3-3.7 [m, 18 H, CH₃CH₂OCHCH₂OCH₂, P-O-CHCH₂-COO-, N(CH₃)₃], 3.95 (m, 3 H, CH₂OPOCH).

5

EXAMPLE 14

3'-Azido-3'-deoxythymidine-5'-α-carboxyphosphocholine-D,L-3-hexadecyloxy-2-ethoxypropane (Compound AA). This analogue was made in analogous manner to that of 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane from 75 mg of (±)-3-Hexadecyloxy-2-ethoxypropyl phosphocarnitine (0.12 mmol), 32 mg of AZT (0.12 mmol), and 160 mg of DCC (0.8 mmol) to give 41 mg of pure product. ¹H-NMR (CDCl₃): δ 0.87 (t, 3 H, terminal methyl), 1.1-1.3 [m, 29 H, (CH₂)₁₃, CH₃CH₂O], 1.5 (m, 2 H, OCH₂CH₂), 1.8 (s, 3 H, Thymidine CH₃), 2.25 (m, 2 H, Thymidine 2' CH₂), 2.7 [m, 2 H, CH₂N(CH₃)₃], 3.2-4.0 [m, 24 H, CH₃CH₂OCHCH₂OCH₂, CH₂OPOCHCH₂COO, N(CH₃)₃, Thymidine 4' CH, and 5' CH₂], 4.35 (m, 1 H, Thymidine 3' CH), 6.1 (m, 1 H, Thymidine 1' CH), 7.4 (s, 1 H, Thymidine C₆ proton), 11.3 (bs, 1 H, diimide NH). FAB Mass Spectrum (MH)⁺; Theoretical 817.4840, Observed 817.4867, 3.2 ppm.

EXAMPLE 15Anti-HIV1 Activity of Lipid-Nucleoside

Conjugates. The inhibitory effects of lipid-nucleoside conjugates on the replication of human immunodeficiency virus type 1 (HIV-1) virus in cells was examined by the plaque assay procedure of L. Kucera et al., Aids Research and Human Retroviruses 6, 491 (1990). In brief, CEM-SS cell monolayers were infected with HIV-1. Infected cells were overlaid with RPMI-1640 plus 10% FBS supplemented with different concentrations of inhibitor. AZT and dideoxyinosine (DDI) were used as positive controls. Plaques were counted at five days after infection. In this assay HIV-1 syncytial plaques

are seen as large, multicellular foci (10 to 25 nuclei/syncytium) that appear either brown and granular or clear. Since the number of HIV-1 syncytial plaques correlates with reverse transcriptase (RT) and p24 core antigen activity in the HIV-1 infected cell overlay fluids, the syncytial plaque assay can be used to quantify the amount of infectious virus. Reverse transcriptase activity was assayed according to a described procedure (B. J. Poiesz et al., Proc. Natl. Acad. Sci. (U.S.A.) 77, 7415 (1980)). The activity of p24 core antigen induced by HIV-1 infection of CEM-SS cells was measured spectrophotometrically using the commercial Coulter EIA.

The results (Table 1) showed that all the lipid-nucleoside conjugates tested have an IC_{50} against HIV-1 syncytial plaque formation ranging from 0.02 to 1.56 μM . The conjugates IC_{50} for cell cytotoxicity ranged from 25.2 to $>100 \mu M$. Of interest are data indicating that the differential selectivity for the conjugates ranged from >64 to 1793 compared to 1400 for AZT and >59 for DDI. The highest differential selectivity (1793) was obtained with the amidoalkyl lipid-AZT conjugate. The increased differential selectivity of the amidoalkyl lipid-AZT conjugate over AZT alone (1400) is due to about a ten-fold decrease in cell cytotoxicity of the amidoalkyl lipid-AZT conjugate ($IC_{50} = 53.8 \mu M$) compared to AZT ($IC_{50} = 5.6 \mu M$). The differential selectivity of the amidoalkyl lipid-AZT is about ten-fold higher than the phosphatidyl AZT prodrug reported by K. Hostetler et al., J. Biol. Chem. 265, 6112 (1990).

TABLE 1

Effect of Nucleoside Analog Alone and Ether Lipid Nucleoside Analog Covalent Conjugates on HIV-1 Plaque Formation and Cell Cytotoxicity

5

		Inhibitory Concentration ₅₀ HIV-1 Plaque Formation	(μM) For: Cell Cyto- toxicity	Differential Selectivity ¹
10	A	0.03 ± 0.02	53.8 ± 7.8	1793
	D	1.56 ± 0.8	> 100	> 64
	B	0.03 ± 0.02	35.0 ± 2.1	1167
	C	0.02 ± 0.01	29.2 ± 5.7	1465
	E	0.02 ± 0.01	25.2 ± 1.1	1260
15	AZT	0.004 ± 0.001	5.6 ± 0.8	1400
	DDI	1.7	> 100	> 59

¹Differential selectivity = ratio IC₅₀ for cytotoxicity + IC₅₀ for HIV-1 plaque formation.

EXAMPLE 16

20 **Anti-HIV-1 Activity of Lipid-Nucleoside Conjugates Over Time.** The effect of Compound A on HIV-1 acutely infected H9 cells and persistently infected H9IIIB cells was evaluated by measuring reverse transcriptase (RT) and infectious virus production in
25 supernatant fluids harvested at various times (days) after HIV-1 infection and continuous treatment with compound A. The results (Table 2) indicated that Compound A caused a marked inhibition of both reverse transcriptase (RT) and infectious HIV-1 production in
30 continuously treated and acutely infected H9 cells. In persistently infected H9IIIB cells, Compound A had little effect on RT activity but a marked inhibition of infectious HIV-1 production (Table 2). The best
35 interpretation of these results is that Compound A inhibits reverse transcription and integration of

-27-

provirus DNA and infectious virus production in HIV-1
acutely infected cells. In persistently infected cells
that already have integrated provirus DNA before
treatment, Compound A markedly inhibits infectious
5 virus production.

TABLE 2

Effect of Long-Term Amide Ether Lipid-AZT Covalent Conjugate (Compound A) Treatment
on HIV-1 Replication in Acutely Infected H9 Cells and Persistently H9IIIB Cells

	Condition of Cells	RT DPM (& Inhibition by CP-92) at:					
		7 Days Post Treatment		21 Days Post Treatment		28 Days Post Treatment	
5	H9 + HIV-1	7	14	21	28	35	42
		172	93,173	47,500	33,110	26,979	42,130
	H9 + HIV-1 + Compound A	(100)	(100)	(97)	(92)	(97)	(98)
							50
							46,331
							(67)
10	H9IIIB + HIV-1	11,045	17,788	22,660	22,056	32,708	46,881
		(0)	(18)	(33)	(0)	(26)	(28)
	H9IIIB + HIV-1 + Compound A						(0)
							32,237
							(0)
15	Condition of Cells	Syncytial Plaque Count Per ML (% Inhibition by CP-92) at:					
		7 Days Post Treatment		21 Days Post Treatment		28 Days Post Treatment	
	H9 + HIV-1	7	14	21	28	35	42
		346	20,640	11,042	6,986	3,894	ND ¹
	H9 + HIV-1 + Compound A	(43)	(98)	(96)	(94)	(95)	ND
							ND
	H9IIIB + HIV-1	7,706	6,638	8,960	8,000	12,450	ND
		(87)	(91)	(91)	(89)	(95)	ND
	H9IIIB + HIV-1 + Compound A						ND
							ND

¹Not determined.

EXAMPLE 17**Anti-HIV1 Activity of Lipid-Nucleoside
Conjugates in Monocyte/Macrophages.**

Monocyte/macrophages represent a major reservoir of
5 HIV-1 in the infected human host. See L. Epstein et
al., AIDS Res. 14, 447 (1984). However, these cells
tend to be resistant to dideoxynucleoside prodrugs due
to low levels of kinases needed to activate the
prodrugs. See C. Perno et al., J. Exp. Med. 168, 1111
10 (1984). To test the compounds of the present invention
in these cells, we treated HIV-1 persistently infected
monocyte/macrophage (U1) cells with AZT and Compound A
and measured the effect on HIV-1 replication. The
results (Table 3) indicate that the compounds did not
15 significantly inhibit HIV-1 induced RT and p24 core
antigen production. As expected, AZT alone caused only
13% inhibition of infectious HIV-1 production.
However, Compound A inhibited infectious HIV-1
production by 33%.

20

TABLE 3

*Effect of AZT and Lipid-Nucleoside Conjugate on
HIV-1 Induced RT, p24 Core Antigen Synthesis
and Infectious Virus Production in
Persistently Infected Monocyte/Macrophage Cells*

25

	<u>Compound</u>	<u>(RT DPM)</u>	<u>Percent of Control</u>	
			<u>(p24 Core Ag)</u>	<u>(PFU)</u>
30	Control	(79,328) 100	(94) 100	(750) 100
	+ AZT	90	101	87
	+ Compound A	121	84	67

EXAMPLE 18

35

**(±)-3-Octadecanamido-2-ethoxypropyl
phosphocarnitine benzyl ester.** This compound was made

-30-

in a similar manner to that of (\pm)-3-hexadecyloxy-2-ethoxypropyl phosphocarnitine benzyl ester from 206 mg of 3-octadecanamido-2-ethoxypropyl phosphatidic acid, 766 mg of the benzyl ester of carnitine as the

5 tetraphenylborate salt, and 400 mg of triisopropylbenzenesulfonyl chloride giving 74 mg of product (32%). $^1\text{H-NMR}$ (CDCl_3): δ 0.87 (t, 3 H, terminal methyl), 1.1 (t, 3H, OCH_2CH_3), 1.2-1.4 [m, 28 H, (CH_2)₁₄], 1.5 (m, 2 H, $\text{NHCOCH}_2\text{CH}_2$), 2.1 (t, NHCOCH_2), 2.7

10 (m, 2H, $\text{P-O-CHCH}_2\text{-COO-}$), 3.0-3.7 [m, 16 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NHCO}$, $\text{CH}_2\text{N}(\text{CH}_3)_3$], 3.9 (m, 3 H, CH_2OPOCH), 5.1 (m, 2 H, $\text{OCH}_2\text{C}_6\text{H}_5$), 6.85 and 6.95 (m, 1H, NH diastereomers), 7.35 (bs, 5 H, C_6H_5).

EXAMPLE 19

15 (\pm)-3-Octadecanamido-2-ethoxypropyl phosphocarnitine. The above benzyl ester (74 mg) was hydrogenated at 15 psi using a catalytic amount of Pd/C to give 53 mg of product (83%). $^1\text{H-NMR}$ (CDCl_3): δ 0.87 (t, 3 H, terminal methyl), 1.1 (t, 3H, OCH_2CH_3), 1.2-1.4

20 [m, 28 H, (CH_2)₁₄], 1.5 (m, 2 H, $\text{NHCOCH}_2\text{CH}_2$), 2.1 (t, NHCOCH_2), 2.7 (m, 2 H, $\text{P-O-CHCH}_2\text{-COO-}$), 3.3-4.0 [m, 18 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NHCO}$, $\text{CH}_2\text{N}(\text{CH}_3)_3$, CH_2OPOCH], 5.1 (m, 1H, OPOCH), 6.9 (m, 1H, NH).

EXAMPLE 20

25 3'-Azido-3'-deoxythymidine-5'- α -carboxyphosphocholine-D,L-3-octadecanamido-2-ethoxypropane (compound BB). This analogue was made in analogous manner to that of 3'-azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane

30 from 48 mg of (\pm)-1-octadecanamido-2-ethoxypropyl phosphocarnitine, 17 mg of AZT, 11 mg of N,N-dimethylaminopyridine, and 87 mg of DCC to give 8 mg of pure product (15% yield). $^1\text{H-NMR}$ (CDCl_3): δ 0.87 (t, 3 H, terminal methyl), 1.1 (t, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 1.2-1.4 [m, 28 H, (CH_2)₁₄], 1.5 (m, 2 H, $\text{NHCOCH}_2\text{CH}_2$), 1.8 (s, 3 H,

35

-31-

Thymidine CH_3), 2.1 (t, 2H, NHCOCH_2), 2.2-2.7 (m, 4H, Thymidine 2' CH_2 , $\text{P-O-CHCH}_2\text{-COO-}$), 3.2-4.1 [m, 22 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NHCO}$, CH_2OPO , $\text{CH}_2\text{N}(\text{CH}_3)_3$, Thymidine 4' CH , and 5' CH_2], 4.6-5.5 (m, 3H, Thymidine 3' CH , OPOCH ,
 5 Thymidine 1' CH), 6.9 (m, 2H, Thymidine C6 proton, NH).

EXAMPLE 21

3'-Azido-3'-deoxythymidine-5'-diphosphate-D,L-3-octadecanamido-2-ethoxypropane (Compound H). 3-Octadecanamido-2-ethoxypropyl phosphatidic acid (36 mg,
 10 0.08 mmol) was azeotropically dried with pyridine (3 ml) three times. AZT 5'-monophosphate morpholidate (25 mg, 0.06 mmol) was added and the drying repeated four times. An additional 3 ml of pyridine was added and the reaction allowed to continue for 96 hours at room
 15 temperature under nitrogen. After removal of the pyridine under vacuum, the resulting oil was chromatographed on 2 g of silica gel eluting with chloroform:methanol (65:35) to chloroform:methanol:water (65:35:1 to 65:35:4). Impure
 20 fractions were collected and rechromatographed using as eluent, chloroform to chloroform:methanol (9:1 to 2:1) to chloroform:methanol:water (2:1:0.1 to 2:1:0.4). The resulting pure product was dissolved in chloroform:methanol:water (4:6:1) and converted to the
 25 sodium salt by stirring twice with Na^+ ion-exchange resin (1.5 g) for one hour. $^1\text{H-NMR}$ (CD_3OD): δ 0.8 (t, 3 H, terminal methyl), 1.1 (t, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 1.2-1.4 [m, 28 H, $(\text{CH}_2)_{14}$], 1.55 (m, 2 H, $\text{NHCOCH}_2\text{CH}_2$), 1.8 (s, 3 H, Thymidine CH_3), 2.2 (t, 2H, NHCOCH_2), 2.2-2.5 (m, 2H, Thymidine 2' CH_2), 3.3-3.8 [m, 16 H, $\text{CH}_3\text{CH}_2\text{OCHCH}_2\text{NHCO}$,
 30 $\text{CH}_2\text{N}(\text{CH}_3)_3$] 3.9-4.2 (m, 5H, CH_2OPO , Thymidine 4' CH , and 5' CH_2] 4.6 (m, 1H, Thymidine 3' CH), 6.25 (m, 1H, Thymidine 1' CH), 7.8 (m, 2H, Thymidine C6 proton, NH). FAB Mass Spectrum $(\text{MH}+2\text{Na})^+$; Theoretical 839.3461,
 35 Observed 839.3463, 0.2 ppm.

EXAMPLE 22

3'-Azido-3'-deoxythymidine-5'-diphosphate-D,L-3-hexadecyloxy-2-ethoxypropane (compound A'). This compound is prepared in essentially the same manner as the compounds described above, except that 3-hexadecyloxy-2-ethoxypropyl phosphatidic acid is used as the starting material.

EXAMPLE 23**Anti-HIV1 Activity of Lipid-Nucleoside**

10 **Conjugates.** CEM-SS cells were seeded (50,000 cells/ml RPMI-1640 growth medium) as a monolayer in 96-well dishes, inoculated with 50 to 100 plaque forming units of HIV-1 and overlaid with serial dilutions of lipid-nucleoside conjugate in RPMI-1640 growth medium.

15 Plaques were counted after five days incubation at 37°C to determine the 50% inhibitory concentration.

To determine the IC₅₀ for cell growth, CEM-SS cells in suspension culture (10,000 cells/ml RPMI-1640 growth medium) were incubated with serial dilutions of compound at 37°C for 48 hours and then pulsed labelled with 1 microCi of ³H-Tdr (SA = 20 Ci/mmol) for 8 hours at 37°C to measure DNA synthesis. Data are given in Table 4 below.

TABLE 4

5

10

EFFECT OF LIPID-NUCLEOSIDE CONJUGATES ON HIV-1 PLAQUE FORMATION			
IC ₅₀ (Micromolar) ^a			
Drug	HIV-1 Plaque Formation	CEM-SS Cell Growth	D.S. ^b
AZT	0.004	5.1	1281
AA	0.004	13.5	3375
BB	0.04	13.7	342
H	0.011	6.6	600
A'	1.27	>100	>78.7


^aConcentration required to inhibit 50% of either plaque formation or CEM-SS cell growth.

^bDifferential selectivity (D.S.) equals the average IC₅₀ for CEM-SS cell growth divided by the average IC₅₀ for HIV-1 plaque formation.

15 The foregoing examples are illustrative of
the present invention, and are not to be construed as
limiting thereof. For example, those skilled in the
art will appreciate that minor changes can be made in
the compounds disclosed herein which will not
significantly adversely affect the activity and
20 usefulness thereof. Accordingly, the invention is
defined by the following claims, with equivalents of
the claims to be included therein.

THAT WHICH IS CLAIMED IS:

1. A lipid-nucleoside covalent conjugate or a salts thereof having the formula:



wherein:

- 20 R_1 is C10-C20 saturated or unsaturated alkyl containing not more than three double bonds;
- R_2 is H or C1-C20 saturated or unsaturated alkyl containing not more than three double bonds; W_1 is S, O, $\text{NHC}(=\text{O})$, or NH;
- 25 W_2 is S, O, $\text{NHC}(=\text{O})$, $\text{OC}(=\text{O})$, NH, or a covalent bond;
- n is zero or one.
- X_1 and X_2 are each independently oxygen or a covalent bond, subject to the proviso that when n is
- 30 zero, then at least either X_1 or X_2 is O;
- Y is H, F, or N_3 ; Z is H or F; or Y and Z together are a covalent bond; and
- B is selected from the group consisting of adenine, thymine, cytosine, guanine, hypoxanthine,
- 35 uracil, 5-fluoro-cytosine, 2-fluoro-adenine, 2-chloro-adenine, 2-bromo-adenine, and 2-amino-adenine.

2. A lipid-nucleoside conjugate according to claim 1, wherein R_1 is C16-C18 linear alkyl containing not more than one double bond.

3. A lipid-nucleoside conjugate according to claim 1, wherein R_2 is H or C1-C3 alkyl.

4. A lipid-nucleoside conjugate according to claim 1, wherein W_1 is $NHC(=O)$.

5. A lipid-nucleoside conjugate according to claim 1, wherein W_2 is O.

6. A lipid-nucleoside conjugate according to claim 1, wherein Y is H or N_3 ; Z is H or F; or Y and Z together are a covalent bond.

7. A lipid-nucleoside conjugate according to claim 1, wherein Y is N_3 , Z is H, and B is thymine.

8. A lipid-nucleoside conjugate according to claim 1, wherein n is 1, X_1 is O, and X_2 is O.

9. A lipid-nucleoside conjugate according to claim 1, wherein n is 1, X_1 is a covalent bond, and X_2 is O.

10. A lipid-nucleoside conjugate according to claim 1, wherein n is 1, X_1 is O, and X_2 is a covalent bond.

11. A lipid-nucleoside conjugate according to claim 1, wherein n is 1, X_1 is a covalent bond, and X_2 is a covalent bond.

12. A lipid-nucleoside conjugate according to claim 1, wherein n is zero, X_1 is O, and X_2 is O.

13. A lipid-nucleoside conjugate according to claim 1, wherein n is zero, X_1 is a covalent bond, and X_2 is O.

14. A lipid-nucleoside conjugate according to claim 1, wherein n is zero, X_1 is O, and X_2 is a covalent bond.

15. A lipid-nucleoside conjugate according to claim 1 which is 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane.

16. A lipid-nucleoside conjugate according to claim 1 which is 3'-Azido-3'-deoxythymidine-5'-monophosphate-D,L-3-hexadecyloxy-2-ethoxypropane.


17. A lipid-nucleoside conjugate according to claim 1 which is 3'-azido-3'-deoxythymidine-5'-monophosphate-D,L-3-hexadecylthio-2-methoxypropane.

18. A lipid-nucleoside conjugate according to claim 1 which is 2',3'-dideoxyinosine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypropane.

19. A lipid-nucleoside conjugate according to claim 1 which is 3'-Azido-3'-deoxythymidine-5'-phosphono-D,L-3-hexadecyloxy-2-methoxypropane.

20. A lipid-nucleoside conjugate according to claim 1 which is 3'-azido-3'-deoxythymidine-5'-monophosphate-D,L-3-octadecanamido-2-hexadecyloxypropane.

21. A lipid-nucleoside conjugate or a salt thereof having the formula:



wherein:

X is S, O, NHC(=O), OC(=O), or NH;

R' is linear or branched, saturated or unsaturated C10-C20 alkyl containing not more than four double bonds, linear or branched, saturated or unsaturated C10-C20 acyl containing not more than four double bonds, phenyl, or naphthyl;

R'' is C5 to C6 cycloalkylene, or a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon chain containing 2-8 carbon atoms, which is unsubstituted or substituted one or more times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino, C1-C20 alkyl, or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy;

m is zero or one;


X₁ and X₂ are each independently oxygen or a covalent bond, subject to the proviso that when m is zero, then at least either X₁ or X₂ is O;

n is 1 to 3;

R₁₃, R₁₄, and R₁₅ are each independently either hydrogen or methyl;

-38-

Nuc is:



wherein:

Y' is H, F, or N₃; Z is H or F; or Y' and Z' together are a covalent bond; and

B' is selected from the group consisting of adenine, thymine, cytosine, guanine, hypoxanthine, uracil, 5-fluoro-cytosine, 2-fluoro-adenine, 2-chloro-adenine, 2-bromo-adenine, and 2-amino-adenine.

22. A lipid-nucleoside conjugate according to claim 21 above, wherein X is NHC(=O).

23. A lipid-nucleoside conjugate according to claim 21 above, wherein R' is C14-C20 linear saturated or unsaturated alkyl containing not more than three double bonds.

24. A lipid-nucleoside conjugate according to claim 21 above, wherein R' is C16-C18 linear alkyl containing not more than one double bond.

25. A lipid-nucleoside conjugate according to claim 21 above, wherein R'' is C2-C4 linear alkyl which is unsubstituted or is substituted one or two times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy.

26. A lipid-nucleoside conjugate according to claim 21 above, wherein R" is linear C2-C4 alkyl which is unsubstituted or substituted one or two times by hydroxyl, phenyl, C1-C20 acyloxy, C1-C20 alkylthio, C1-C20 acylated amino or by C1-C20 alkoxy which is unsubstituted or is substituted by phenyl or C1-C5 alkoxy.

27. A lipid-nucleoside conjugate according to claim 21 above, wherein n is 1.

28. A lipid-nucleoside conjugate according to claim 21 above, wherein R₁₃, R₁₄, and R₁₅ are methyl.

29. A lipid-nucleoside conjugate according to claim 21 above, wherein Y' is H or N₃; Z' is H; or Y' and Z' together are a covalent bond.

30. A lipid-nucleoside conjugate according to claim 21 above, wherein Y' is H or N₃ and Z' is H.

31. A lipid-nucleoside conjugate according to claim 21, comprising 3'-Azido-3'-deoxythymidine-5'-butyrate-γ-N,N,N-trimethyl-ammonium-β-(1-phospho-2-ethoxy-3-hexadecyloxypropane).

33. A lipid-nucleoside conjugate according to claim 21, comprising 3'-Azido-3-deoxythymidine-5'-butyrate-γ-N,N,N-trimethyl-ammonium-β-(1-phospho-2-ethoxy-3-octadecanamidopropane).

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/04289

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C07H 17/00; A61K 31/70

U.S.C1.: 536/27,28,29; 514/49,51,12,808

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.C1.	536/27,28,29; 514/49,51,12,808

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁸

APS, CAS

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<u>Y</u> A	US, A, 4,291,024 (TURCOTTE) 22 September 1981, see entire document.	<u>1-20</u> 21-33
<u>Y</u> A	US, A, 4,622,392 (HONG ET AL.) 11 November 1986, see abstract.	<u>1-20</u> 21-33
<u>Y</u> A	US, A, 4,797,479 (SHUTO ET AL.) 10 January 1989, see abstract.	<u>1-20</u> 21-33
<u>Y</u> A	US, A, 4,921,951 (SHUTO ET AL.) 01 May 1990, see abstract.	<u>1-20</u> 21-33

* Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

22 August 1991

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

20 SEP 1991

Signature of Authorized Officer

Anita Varma
Anita Varma

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET	
V. <input type="checkbox"/> OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹	
This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:	
1. <input type="checkbox"/> Claim numbers because they relate to subject matter ¹² not required to be searched by this Authority, namely:	
2. <input type="checkbox"/> Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³ , specifically:	
3. <input type="checkbox"/> Claim numbers because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).	
VI. <input checked="" type="checkbox"/> OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²	
This International Searching Authority found multiple inventions in this international application as follows:	
Seeh attached sheet.	
1. <input checked="" type="checkbox"/> As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. telephone practice	
2. <input type="checkbox"/> As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:	
3. <input type="checkbox"/> No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:	
4. <input type="checkbox"/> As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.	
Remark on Protest	
<input type="checkbox"/> The additional search fees were accompanied by applicant's protest.	
<input type="checkbox"/> No protest accompanied the payment of additional search fees.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
$\frac{Y}{A}$	WO, A, 90/00555 (HOSTETTER ET AL.) 25 January 1990, see entire document.	$\frac{1-20}{21-33}$
$\frac{Y}{A}$	JOURNAL OF MEDICINAL CHEMISTRY, Vol. 33, No. 5, issued 1990. Chung Hong et al., "Nucleoside Conjugate II. Synthesis and Antitumor Activity of 1-B-D-Acabinofuranosylcytosine and Cystine Conjugates in Thioether Lipids", pages 1380-1386, see entire document.	$\frac{1-20}{21-33}$
Y	AIDS RESEARCH AND HUMAN RETROVIRUSES, Volume 6, No. 4, issued 1990, L.S. Kucera et al., "Novel Membrane-Interactive Ether Analogs that Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation, pages 491-501, see the entire document.	1-33

ATTACHMENT TO PCT/ISA/210:

The claims of the instant PCT are drawn to following inventions:

I. Claims 1-20 are, drawn to phospholipid-nucleoside conjugates, classified in Class 536, subclass 27-29.

II. Claims 21-33 are, drawn to Carnitine-nucleoside, classified in Class 536, subclass 27-29.

The inventions are distinct, each from the other because of the following reasons:

The claims of these two groups are drawn to distinct inventions which are not linked so as to form a single general inventive concept.

The claims of Group I and Group II are drawn to distinct products, and PCT Rule 13.1 and 13.2 do not provide for multiple distinct products within a single general inventive concept.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.